With regards to hypercoagulability, the complement inhibitor compounds in active COVID-19 clinical trials likely have minimal effects; these primarily target the expression of tissue factor and plasminogen activator inhibitor-1 [24]. The gene discussed is F3; the disease is thrombophilia.